Search results
Showing 2596 to 2610 of 7685 results
Artificial intelligence technologies for mammography: early value assessment
Awaiting development [GID-HTE10062] Expected publication date: TBC
Digital platforms to support self-management of asthma : early value assessment
Awaiting development [GID-HTE10063] Expected publication date: TBC
Seladelpar for previously treated primary biliary cholangitis ID6429
In development [GID-TA11540] Expected publication date: 10 September 2025
In development [GID-TA11498] Expected publication date: 10 September 2025
Tofersen for treating amyotrophic lateral sclerosis caused by SOD1 gene mutations [ID3767]
In development [GID-HST10062] Expected publication date: TBC
Balloon disimpaction of the baby's head at emergency caesarean during the second stage of labour
In development [GID-IPG10408] Expected publication date: 16 April 2025
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]
In development [GID-TA11630] Expected publication date: 11 September 2025
Vutrisiran for treating transthyretin-related amyloidosis with cardiomyopathy [ID6470]
In development [GID-TA11598] Expected publication date: TBC
E‑vita open plus for treating complex aneurysms and dissections of the thoracic aorta (MTG16)
Evidence-based recommendations on the E-vita open plus for treating complex aneurysms and dissections of the thoracic aorta.
Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care (MTG65)
Evidence-based recommendations on Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care.
View recommendations for MTG65Show all sections
Evidence-based recommendations on Alpha-Stim AID for managing anxiety disorders.
View recommendations for MTG56Show all sections
Evidence-based recommendations on the ReCell Spray-On Skin system for treating skin loss, scarring and depigmentation after burn injury.
Evidence-based recommendations on viscoelastometric point-of-care testing devices (the ROTEM, TEG and Sonoclot systems)
Fluorouracil chemotherapy: The My5‑FU assay for guiding dose adjustment (DG16)
Evidence-based recommendations on the My5-FU assay for measuring levels of 5-flurouracil (5-FU) in patients having chemotherapy, to help guide changes to the
Evidence-based recommendations on therapeutic monitoring of tumour necrosis factor (TNF)-alpha inhibitors (LISA-TRACKER, IDKmonitor and Promonitor ELISA kits) in people with Crohn’s disease